Posted by Michael Wonder on 27 Mar 2025
ViiV Healthcare announces reimbursement for Apretude for HIV-1 pre-exposure prophylaxis under the Non-Insured Health Benefits (NIHB) Program
25 March 2025 - ViiV Healthcare is pleased to announce that Apretude (cabotegravir tablets and extended release injectable suspension) is now covered under the federal Non-Insured Health Benefits Program for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in at risk individuals who are HIV-1 negative.
The Non-Insured Health Benefits Program provides eligible First Nations and Inuit people with coverage for a range of health benefits that are not otherwise covered through private, provincial, or territorial health insurance plans or social programs.
